However, there was no significant difference in BG control between the glargine-SSI and SSI-only

groups. Prospective studies involving more patients are needed to show possible clinically significant benefits of this intervention.”
“Background: Sleep disturbance in midlife women has been studied extensively, although less is known about sleep after menopause. This study examined the relative impact of sociodemographics, modifiable lifestyle factors, and health status on sleep disturbance in postmenopausal women from Queensland, Australia. Methods: The longitudinal Healthy Aging of Women (HOW) Study examines health-related quality of life (HRQOL measured by the 12-item Short Form [SF-12((R))] survey [Medical Outcomes Trust, Hanover, CA]); chronic illness; modifiable

lifestyle factors, such as physical Sotrastaurin supplier activity, alcohol consumption, smoking; and sleep disturbance (General Sleep Disturbance Scale [GSDS] (Lee, San Francisco, CA) 43 represents poor sleep) in midlife and older women from low- and high-socioeconomic rural and urban areas of South East Queensland, Australia. This article presents cross-sectional Selleck P5091 data from the 322 women, aged 60-70 years, participating in the HOW study in 2011. Results: For women in this study, sleep disturbance was relatively common, with 23% (n=83) reporting poor sleeping (GSDS 43). Sleep-disturbance scores were strongly correlated with being unemployed or on a disability support pension (=18.69, p<0.01), sedentary lifestyle (=23.84, p<0.01), and lower mental (=-0.60, p<0.01) and physical HRQOL scores (=-0.32, p=0.01), and these variables explained almost one-third of variance in sleep-disturbance scores ((2)=29%). Conclusions: Multivariable analysis revealed that sleep disturbance was correlated with physical and mental HRQOL, disability, and sedentary lifestyle but not other lifestyle and sociodemographic characteristics. It may be, however, that modifiable

lifestyle factors may indirectly impact sleep by influencing health status.”
“Background: Gut secreted incretin hormones and gastric bypass surgery currently provides some of the most successful treatments for diabetes and obesity respectively. However, despite the evident importance of the gut endocrine CH5424802 ic50 system no information exists on the total number and distribution of different types of endocrine cells in the gut. Here we have used the established preclinical Zucker Diabetic Fatty (ZDF) rat model which displays elevated levels of GLP-1 to assess L-cell distribution and L-cell dynamics in the full rostro-caudal extension of the rat intestinal tract. Methods: Using mathematically unbiased stereology we provide total and regional estimates of gut volume, gut surface area and the total number of L-cells throughout the intestinal tract in obese ZDF rats and lean controls. Results: The total number of L-cells in the lean and obese ZDF gut is estimated to 4.8 and 10.